KSE - Delayed Quote KRW

SK bioscience Co.,Ltd. (302440.KS)

40,000.00
+450.00
+(1.14%)
At close: 3:30:05 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
267,545,049.15
267,545,049.15
369,505,555.85
456,725,871.19
929,000,929.90
Cost of Revenue
236,569,373.42
236,569,373.42
227,262,753.95
217,114,929.80
358,717,802.80
Gross Profit
30,975,675.73
30,975,675.73
142,242,801.90
239,610,941.39
570,283,127.10
Operating Expense
169,406,974
169,406,974
154,230,567
124,597,324
96,063,271
Operating Income
-138,431,298.27
-138,431,298.27
-11,987,765.10
115,013,617.39
474,219,856.10
Net Non Operating Interest Income Expense
3,293,170.41
3,293,170.41
12,157,215.03
2,393,503.80
-1,910,409.17
Pretax Income
-89,106,828.35
-89,106,828.35
7,327,227.38
141,733,182.45
471,128,180.52
Tax Provision
-38,989,757.89
-38,989,757.89
-14,990,491.85
19,281,232.52
115,988,903.68
Net Income Common Stockholders
-53,881,198.90
-53,881,198.90
22,317,719.23
122,451,949.93
355,139,277
Basic EPS
-698.00
--
291.00
1.60k
4.84k
Diluted EPS
-698.00
--
290.00
1.59k
4.81k
Basic Average Shares
77,193.70
--
76,693.19
76,724.28
73,315.29
Diluted Average Shares
77,193.70
--
76,957.65
77,013.81
73,833.53
Total Operating Income as Reported
-138,431,298
-138,431,298
-11,987,764.77
115,013,617.84
474,219,856.32
Rent Expense Supplemental
928,102
928,102
153,861
141,753
60,772
Total Expenses
405,976,347.42
405,976,347.42
381,493,320.95
341,712,253.80
454,781,073.80
Net Income from Continuing & Discontinued Operation
-53,881,198.90
-53,881,198.90
22,317,719.23
122,451,949.93
355,139,277
Normalized Income
-74,845,773.06
-74,845,773.06
30,609,793.47
116,690,077.88
358,389,721.14
Interest Income
6,978,080
6,978,080
13,555,354
4,854,444
1,516,518
Interest Expense
3,684,910
3,684,910
1,398,139
2,460,940
3,426,927
Net Interest Income
3,293,170.41
3,293,170.41
12,157,215.03
2,393,503.80
-1,910,409.17
EBIT
-85,421,918.35
-85,421,918.35
8,725,366.38
144,194,122.45
474,555,107.52
EBITDA
-36,196,684.35
-36,196,684.35
43,490,069.38
171,430,531.45
493,330,412.52
Reconciled Cost of Revenue
236,569,373.42
236,569,373.42
227,262,753.95
217,114,929.80
358,717,802.80
Reconciled Depreciation
49,225,234
49,225,234
34,764,703
27,236,409
18,775,305
Net Income from Continuing Operation Net Minority Interest
-53,881,198.90
-53,881,198.90
22,317,719.23
122,451,949.93
355,139,277
Total Unusual Items Excluding Goodwill
27,584,966
27,584,966
-10,910,624
6,669,134
-4,312,043
Total Unusual Items
27,584,966
27,584,966
-10,910,624
6,669,134
-4,312,043
Normalized EBITDA
-63,781,650.35
-63,781,650.35
54,400,693.38
164,761,397.45
497,642,455.52
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
6,620,391.84
6,620,391.84
-2,618,549.76
907,261.95
-1,061,598.86
12/31/2021 - 3/18/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

344860.KQ INNOGENE Co.,Ltd.
2,065.00
+0.73%
 
475960.KQ TOMOCUBE
26,700.00
+27.14%
 
000504.SZ Landfar Bio-medicine Co., Ltd
6.67
-3.33%
 
203400.KQ ABION Inc.
6,050.00
+3.07%
 
7774.T Japan Tissue Engineering Co., Ltd.
605.00
+0.83%
 
130A.T VERITAS IN SILICO INC
647.00
+1.89%
 
347850.KQ D&D Pharmatech
89,700.00
+26.34%
 
086900.KQ Medy-Tox Inc.
164,000.00
+2.24%
 
CONCORDBIO.BO Concord Biotech Limited
1,506.15
-0.48%
 
4565.T Nxera Pharma Co., Ltd.
852.00
0.00%